CE / CME
Downloadable slideset on CDK4/6 inhibitors in HR+/HER2- breast cancer from early stage through metastatic disease.
Activity Accreditation Release: June 25, 2024
Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™
ABIM MOC: maximum of 1.00 Medical Knowledge MOC point
Released: May 30, 2024
Expiration: May 29, 2025
Share
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington
Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas
Provided by Clinical Care Options, LLC.
Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.
Lilly
Novartis Pharmaceuticals Corporation
This program is intended for medical oncologists and other healthcare professionals who treat patients with breast cancer.
The goal of this program is to inform and build the necessary skills of target learners to optimize their care of patients with high-risk HR-positive/HER2-negative breast cancer.
Upon completion of this activity, participants should be able to:
Assess risk in patients with HR+/HER2- EBC and MBC to guide optimal therapy selection in order to improve clinical outcomes
Select individualized adjuvant therapies for patients with high-risk, HR+/HER2- EBC based on tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
Plan an individualized sequence of therapies for patients with HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
Implement evidence-based management of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer
Promote adherence to and persistence with oral therapies targeting CDK4/6 in patients with HR+/HER2- breast cancer
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Primary Author
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Head, Division of Hematology and Oncology
Department of Medicine, UW Medicine
Senior Vice President
Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington
Sara A. Hurvitz, MD, FACP: researcher: Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Celcuity, CytomX, Daiichi Sankyo, Dantari, Dignitana, Genentech/Roche, G1 Therapeutics, Gilead, Greenwich, Life Sciences, GlaxoSmithKline, Immunomedics, Lilly, Loxo, MacroGenics, Novartis, OBI Pharma, Orinove, Orum, Pfizer, Phoenix Molecular Designs, Puma, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks; individual publicly traded stock/stock options: ROM Tech.
Erica L. Mayer, MD, MPH
Director of Breast Cancer Clinical Research
Dana-Farber Cancer Institute
Associate Professor in Medicine
Harvard Medical School
Boston, Massachusetts
Erica L. Mayer, MD, MPH: consultant/advisor/speaker: Arvinas, AstraZeneca, Lilly, Novartis.
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Chair, Breast Disease Committee
Sarah Cannon Research Institute
Texas Oncology
Dallas, Texas
Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, Bydonis, Carrick Therapeutics, BioNTech, Daiichi Sankyo, Dava Oncology, Eisai, Fishawack Health, G1 Therapeutics, Genzyme, GlaxoSmithKline, Genentech, Gilead Sciences, Lilly, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre Pharmaceuticals, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Veru.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 25, 2024, through May 29, 2025:
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).
CME Passport
The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.